2003 Annual Report

We are pleased to provide this on-line excerpt of the IPTR Annual Report 2003.  To request a complete print copy, please refer to the Contact Us page.

Please Note: Usual copyright laws apply to this material.  Slides and text may be downloaded, but may not be modified or directly re-displayed on your web site.  Any use of the slides or accompanying text must be appropriately cited and referenced.  Thank you.

Graphs of Analysis Results
Each graph is a 28.8k GIF file.

Contents:

1. Analysis of Data

2. Total Number of Pancreas Transplants for 2003 Annual Report

3. Pancreas Transplants by Category

4. Non-US Survival Rates by Category

5. Non-US Pancreas Graft Duct Management

6. USA SPK, PAK and PTA Patient Survival

7. USA SPK, PAK, PTA Graft Survival & Immunological Graft Loss

8. USA Pancreas Retransplant Graft Survival

9. Historical Era: USA SPK, PAK, PTA Graft Survival (1-year, 5-year, 10-year)

10. USA SPK, PAK, PTA Pancreas Graft Failure Cause 1998-2003

11. Effect of Recipient Age on USA Primary Pancreas Transplant Outcome by Era

12. Effect of Recipient Age on USA Primary Pancreas Transplant Outcome 1998-2003 Cases

13. Effect of Donor Age on USA Pancreas Graft Survival for 1998-2003 Cases

14. Effect of Diabetes Type on USA SPK Outcome for 1998-2003 Cases

15. Effect of Venous Vascular Management on USA ED Pancreas Outcome 1999-2003 Cases

16. Effect of Preservation Time on USA Pancreas Transplant Outcome for 1998-2003 Cases

17. Effect of Center Size on USA Pancreas Transplant Outcome for 1999-2003 Cases

18. USA Pancreas Graft Duct Management

19. Historical Era: USA Pancreas Graft Duct Management

20. USA Technical Failure by Category and Duct Management 1999-2003 cases

21. Historical Era: USA Technical Failure

22. USA Immunosuppression Therapy Initial Maintenance Protocols

23. USA Immunosuppression Therapy Antibody Induction

24. USA Pancreas Graft Outcomes by Induction Therapy

25. SPK Outcome by Induction Therapy

26. PAK Outcome by Induction Therapy

27. PTA Outcome by Induction Therapy

28. USA Pancreas Graft Immunological Loss

29. USA Pancreas Graft Immunological Loss by Human Leukocyte Antigen (HLA)

30. USA Demographics

31. USA Cox Multivariate and Logistic Regression Analyses

32. Summary of Primary Significant Relative Risk Factors

33. Discussion and Summary